Despite the enormous possibilities of RNAi, there still exist many problems that need to be
addressed. Obstacles in delivery, target cell transfection, stability/degradation, transient …

There is a tremendous interest in moving siRNA therapeutics into a clinical setting for the
treatment of various diseases. This in itself however depends largely on the availability of …

siRNA technology presents a helpful means of gene silencing in mammalian cells.
Advancement in the field includes enhanced attentiveness in the characterization of target …

RNA interference (RNAi) was first literaturally reported in 1998 and has become rapidly a
promising tool for therapeutic applications in gene therapy. In a typical RNAi process, small …

Over the last decades, gene therapy has emerged as a pioneering therapeutic approach to
treat or prevent several diseases. Among the explored strategies, the short-term silencing of …

Since the discovery of the “starburst polymer”, later renamed as dendrimer, this class of
polymers has gained considerable attention for numerous biomedical applications, due …

One of the primary limitations of RNA interference as a technique for gene regulation is
effective delivery of siRNA into the target cells. Dendrimers are nanoparticles that are …

A neutral cross-linked dendritic system is described for use of delivering small interfering
RNA (siRNA) for targeted gene silencing. By replacing the terminal amines with hydrazide …

Background: Therapeutic efficacy of dreadful diseases like cancer, HIV (Human
Immunodeficiency Virus) can be enhanced by delivering molecules which regulate function …

Non-viral gene delivery vectors studied in the gene therapy applications are often designed
with the cationic nitrogen containing groups necessary for binding and cell release of …